AbbVie Inc.
North Chicago, Illinois, United States · Biopharma, Biotechnology, Healthcare
Venture capital subsidiary of Abbvie
Key facts
- Headquarters
- North Chicago, Illinois, United States
- Employees
- 59,932
- Industries
- Biopharma, Biotechnology, Healthcare
- Status
- Public (ABBV)
- Website
- www.abbvie.com
- Company page
Recent activity at AbbVie Inc.
- : AbbVie partners with McLaren Racing in a multiyear collaboration to promote liver health awareness through Formula 1.
- : AbbVie Director Resigns Following CEO Appointment at Align Technology
- : Mayo LGFA and AbbVie announce three-year title sponsorship for adult championship. (date Fundz recorded it)
- : AbbVie to acquire Apogee Therapeutics for $10.9B
- : SEC 8-K (5.02):
- : SEC 8-K (5.02): On October 14, 2026, AbbVie Inc. expanded its Board of Directors from twelve to thirteen members by appointing Dr. John M. Carethers as a Class II director. Dr. Carethers, who is currently the Vice Chancellor for Health Sciences at the University of California San Diego, has also previously served as a director of Avantor, Inc. He has been assigned to the Public Policy and Sustainability Committee of AbbVie. The Board confirmed that Dr. Carethers qualifies as an independent director under applicable governance standards. Compensation details for Dr. Carethers' role as an independent director are documented in Exhibit 10.5 of AbbVie’s Quarterly Report for the period ended March 31, 2025.
- : SEC 8-K (2.02): On October 5, 2026, AbbVie Inc. completed a series of debt offerings, issuing senior notes totaling various maturities ranging from 2027 to 2031. The offered notes include 0.750% Senior Notes due 2027, 2.125% Senior Notes due 2028, 2.625% Senior Notes due 2028, 2.125% Senior Notes due 2029, and 1.250% Senior Notes due 2031. This financing aims to support AbbVie’s future growth initiatives and improve its capital structure. Specific financial amounts were not disclosed in the filing, but the issuance is significant for the company's operational expansion.
- : SEC 8-K (7.01): On September 3, 2026, AbbVie Inc. announced the completion of its acquisition of Apogee Therapeutics, Inc. This significant acquisition is expected to enhance AbbVie's portfolio and operational capabilities by integrating Apogee's promising pipeline assets, including zumilokibart (APG777) and APG273. The transaction indicates AbbVie's strategic focus on expanding its therapeutic offerings, although the company acknowledges the risks involved, such as integration challenges and the performance of acquired assets in clinical trials. The financial details of the acquisition have not been disclosed in the filing, but it highlights the anticipated benefits to AbbVie's earnings and market position. The event date is September 3, 2026, marking it as a recent and relevant business transaction.
- : SEC 8-K (8.01): On August 18, 2026, AbbVie Inc. completed its previously announced underwritten public offering of Senior Notes. This offering included various series of notes, with maturities ranging from 2027 to 2031, featuring interest rates from 0.750% to 2.625%. The completion of this public offering indicates the company's strategy to raise capital through debt financing. This transaction may enhance AbbVie's liquidity and support its operational and investment activities.
- : SEC 8-K (8.01): On August 4, 2026, AbbVie Inc. entered into an underwriting agreement with multiple financial institutions to issue and sell a total of approximately $9.93 billion in senior notes and floating rate notes. The offering includes various series of notes with principal amounts ranging from $500 million to $1.5 billion, with due dates extending from 2028 to 2066. The transaction is scheduled to close on August 18, 2026, pending customary conditions. AbbVie intends to utilize the net proceeds from this offering to enhance its financial flexibility and support its operational strategies. This underwriting agreement represents a significant capital raise and reflects AbbVie's ongoing financial activities in the capital markets.
Dates are the day the event happened, taken from the announcement or SEC filing, unless a row says otherwise.
AbbVie Inc. funding history
| Date | Round | Amount |
|---|---|---|
| May 2016 | Venture | $3.8B |
Leadership
- Frederick Waddell, Director
- Glenn Tilton, Director
- Edward Rapp, Director
- Brett Hart, Director
- Edward Liddy, Director
- William Burnside, Director
- Roxanne Austin, Director
- Robert Alpern, Director
- Richard Gonzalez, Executive Officer, Director
- Jennifer L. Davis, Chief Executive Officer
- Michael Ryan, Chief Medical Officer
- Roopal Thakkar, Chief Scientific Officer
Verified email and direct lines for AbbVie Inc.’s decision-makers are on Fundz. See plans or book a 15-minute walkthrough.
Employee benefit plans
AbbVie Inc. files 7 employee benefit plans with the U.S. Department of Labor, including a retirement plan. The next plan year renews in Dec 2026.
AbbVie Inc. in the news
- About Race to Innovate - AbbVie (Oct 20, 2026)
- Real-World Evidence in IBD: Driving Innovative Approaches to Care - AbbVie (Apr 30, 2026)
- Striking Out Cancer by Turning Ks into Ws - AbbVie (Mar 24, 2026)
- I AM - AbbVie (May 15, 2026)
- Empowering Innovation Through the AbbVie Foundation Health Equity Accelerator - AbbVie (Feb 03, 2026)
- AbbVie’s Resilient Global Distribution Network Helps Prevent Drug Shortages - AbbVie (Sep 04, 2025)
- Genomics - AbbVie (Dec 19, 2024)
- Digital Science Lab - AbbVie (Mar 25, 2024)
Companies similar to AbbVie Inc.
- Bristol Myers Squibb · Biopharma, Biotechnology, Health Care, Manufacturing, Pharmaceutical, Therapeutics
- Jazz Pharmaceuticals plc · Biopharma, Biotechnology, Health Care, Manufacturing, Pharmaceutical, Therapeutics
- Teva Pharmaceutical Industries Ltd · Biotechnology, Health Care, Manufacturing, Pharmaceutical, Therapeutics
- Celltrion · Biopharma, Biotechnology, Manufacturing, Pharmaceutical, Therapeutics
- Merck Group · Biotechnology, Health Care, Manufacturing, Pharmaceutical
About AbbVie Inc.: questions and answers
What does AbbVie Inc. do?
Venture capital subsidiary of Abbvie
Where is AbbVie Inc. headquartered?
AbbVie Inc. is headquartered in North Chicago, Illinois, United States.
How many employees does AbbVie Inc. have?
AbbVie Inc. has about 59,932 employees.
Has AbbVie Inc. raised funding?
Yes. Fundz has recorded 1 funding event for AbbVie Inc.. The most recent, $3.8B, was in May 2016.
Who leads AbbVie Inc.?
Jennifer L. Davis is a Chief Executive Officer at AbbVie Inc..
What is the latest news on AbbVie Inc.?
On Nov 3, 2026, AbbVie partners with McLaren Racing in a multiyear collaboration to promote liver health awareness through Formula 1.
Is AbbVie Inc. a public company?
Yes. AbbVie Inc. is publicly traded under the ticker ABBV.
Source: Fundz records from SEC filings, press releases and company announcements. How Fundz measures data accuracy